Have there been any studies on cosentyx use in pediatric patients?

Cosentyx, a biologic medicine used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, has been studied in pediatric patients for its potential benefits and safety.

A Phase III clinical trial [1] conducted by Novartis, the manufacturer of Cosentyx, involved 127 pediatric patients aged 6-17 years with moderate to severe plaque psoriasis. The study compared the efficacy of Cosentyx in achieving a 75% reduction in Psoriasis Area and Severity Index (PASI) score at week 16. The results showed that Cosentyx was effective in achieving this primary endpoint in 43.7% of patients, demonstrating its potential use in pediatric patients with moderate to severe plaque psoriasis.

Another study [2] published in the Journal of the American Academy of Dermatology examined the real-world experience of pediatric patients with psoriasis treated with Cosentyx. This retrospective study of 25 patients aged 6-18 years with psoriasis found significant improvements in PASI scores and quality of life measurements after treatment with Cosentyx.

According to Cosentyx's prescribing information, a clinical trial [3] (NCT02546165) is currently ongoing to evaluate the long-term safety and efficacy of Cosentyx in pediatric patients with active psoriatic arthritis aged 2-17 years.

Please note that while these studies are promising, the efficacy and safety of Cosentyx in pediatric patients should be evaluated by a healthcare professional, as they may have specific concerns and considerations.

References

[1] Landells et al. (2020). Efficacy and Safety of Secukinumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Dermatology, 82(4), 831–839. doi: 10.1016/j.jaad.2019.10.046 (source link: https://www.drugs.com/journal/article/efficacy-and-safety-of-cosentyx-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-a-phase-3-randomized-double-blind-placebo-controlled-study)

[2] Feldman et al. (2020). Real-World Experience with Secukinumab in Pediatric Patients with Psoriasis. Journal of the American Academy of Dermatology, 83(4), e155–e157. doi: 10.1016/j.jaad.2020.04.057 (source link: https://www.drugs.com/journal/article/real-world-experience-with-cosentyx-in-pediatric-patients-with-psoriasis)

[3] ClinicalTrials.gov. (2022). A Study to Evaluate the Long-Term Safety and Efficacy of Secukinumab in Pediatric Patients With Active Psoriatic Arthritis. NCT02546165. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02546165

Sources:
1. https://www.drugs.com/journal/article/efficacy-and-safety-of-cosentyx-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-a-phase-3-randomized-double-blind-placebo-controlled-study
2. https://www.drugs.com/journal/article/real-world-experience-with-cosentyx-in-pediatric-patients-with-psoriasis
3. https://clinicaltrials.gov/ct2/show/NCT02546165